Introduction Executive Summary Acute optic neuritis: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Acute optic neuritis – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Acute optic neuritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends Acute optic neuritis Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Mid Stage Products (Phase II) • Comparative Analysis BN201: Bionure • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis ST-266: Noveome • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Acute optic neuritis Key Companies Acute optic neuritis Key Products Acute optic neuritis- Unmet Needs Acute optic neuritis- Market Drivers and Barriers Acute optic neuritis- Future Perspectives and Conclusion Acute optic neuritis Analyst Views Acute optic neuritis Key Companies Appendix

Table 1 Total Products for Acute optic neuritis Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Bionure • Noveome • Lipocure